| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.2418 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.3295 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.3328 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.3403 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.3404 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.3446 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.3511 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.3527 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.3676 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.3761 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.4106 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.4367 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.4420 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.4649 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.4767 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.4801 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5002 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5125 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5270 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5304 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5308 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5429 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5452 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5494 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5561 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5668 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5728 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5807 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5839 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6019 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6026 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6035 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6153 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6219 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6235 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6360 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6396 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6548 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6566 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6567 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6622 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6773 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6814 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6834 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6878 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6880 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6904 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6943 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7040 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7052 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7078 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7243 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7347 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7527 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7574 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7598 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7681 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7741 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7749 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7858 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7887 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7926 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7931 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8001 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8001 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8089 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8131 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8172 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8268 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8350 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8424 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8589 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8709 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8762 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8801 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8807 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8984 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8998 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9006 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9007 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9060 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9074 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9199 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9240 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9312 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9450 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9482 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9572 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9572 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9605 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9625 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9759 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9797 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0000 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0026 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0108 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0203 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0517 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0785 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0932 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0969 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0978 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1030 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1115 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1165 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1206 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1267 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1273 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1296 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1404 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1497 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1598 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1612 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1635 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1698 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1847 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1852 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1997 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2042 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2365 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2381 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2449 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2506 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2549 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2573 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2604 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2654 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2668 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2788 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2805 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2822 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.3088 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.3107 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.3151 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.3193 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.3351 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.3497 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.3520 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.3694 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.3720 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.4199 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.4358 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.4382 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.4390 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.4502 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.4996 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.5007 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.5081 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.5202 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.5431 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.5536 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.5742 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.5857 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.6035 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.6079 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.6117 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.6440 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.6557 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.6566 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.7083 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.7400 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.7660 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.7842 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.9004 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.1777 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.3375 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.3709 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.3886 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.4138 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.4549 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.5053 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.5110 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.5598 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.7168 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.7223 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.8396 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.8840 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.9252 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 3.0189 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 3.1638 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 3.1682 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 3.1810 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 3.3252 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 3.5046 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 3.5848 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 4.3884 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 4.8482 | scaled units | High-Dose | -0.5HR |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|